This is a limited company view. Sign up for a Free Trial to see everything.

BioVentrix is developing the Revivent treatment, which is a transcatheter-based procedure known as less invasive ventricular enhancement that reduces the overall size of the wall of the heart's left ventricle, without the need for cardiopulmonary bypass or incisions in the heart.

B2B
Biotechnology
Healthcare
Medical Devices
Pharmaceuticals

Overview

Location

Bay Area

Founded

Employees

0

Stage

Series B

Total funding

$24M

Last funding

a year ago

Acquisitions

0

Growth score

38

Mindshare score

38

Scoring

Deals

$8.0M Series B

Jan 27, 2017

$1.2M Convertible Note

Jul 26, 2016

$14.0M Series A

Dec 8, 2015

$360.0K Debt

Telegraph Hill Partners

Oct 1, 2009

Employee Growth

Use BioVentrix's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use BioVentrix's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial